A study from the Clinical Pharmacology Unit, Department of Medicine, Cardiovascular Division, Department of Medicine (N.F.), University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom shows that “DACH1, a Zona Glomerulosa Selective Gene in the Human Adrenal, Activates Transforming Growth Factor-β Signaling and Suppresses Aldosterone Secretion.” This study was published in the 16 March 2015 issue of the journal “Hypertension” by Prof. Brown MJ, Zhou J and others.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: AntagomiR-based therapy for Hypertension: MiRNA-194 increases aldosterone secretion and blood pressure via down regulation of its target gene. This study suggests that miRNA-194, by down regulating its target gene, it may augment the secretion of Aldosterone. Thereby, it may increase blood pressure. Thus, pharmacological formulations encompassing “miRNA-194 inhibitors” may be used in the treatment of hypertension.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., AntagomiR-based therapy for Hypertension: MiRNA-194 increases aldosterone secretion and blood pressure via down regulation of its target gene, Genome-2-Bio-Medicine Discovery center (GBMD), 20/March/2014, 12.26 pm., http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org